Johnson & Johnson (MIL:1JNJ)
€ 217.95 -2.7 (-1.22%) Market Cap: 528.39 Bil Enterprise Value: 557.31 Bil PE Ratio: 28.97 PB Ratio: 7.41 GF Score: 61/100

Johnson & Johnson at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 02:10PM GMT
Joshua Thomas Jennings
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning. I'm Josh Jennings from the Cowen medical devices research team, representing my colleagues, Brian Kennedy, Eric Anderson, [Michael Jackson] and [Ajay Suman]. We are pleased to kick off our track with Mathai Mammen, the Executive Vice President of Pharmaceuticals Research & Development of the Janssen franchise within Johnson & Johnson. Mathai, great to see you this morning. Thanks so much for participating in our conference this year.

Mathai Mammen
Johnson & Johnson - EVP of Pharmaceuticals, R&D

Wonderful to be here. And thank you, Josh.

Questions & Answers

Joshua Thomas Jennings
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So I know you and your team had a big event back in November, and wanted to dig a little bit deeper into the pharma R&D strategy and pipeline. And I'd like to start off with just -- and Janssen has had quite a run, a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot